Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose (scientific article)

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Q28286064

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

Q30435188

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

Q33366403

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

Q33378194

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

Q33380352

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study

Q33396465

The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis

Q33410064

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

Q33418456

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

Q33421147

Bendamustine

Q34257877

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

Q34308997

Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy

Q34322781

New treatment options have changed the survival of patients with follicular lymphoma

Q34561857

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Q34663603

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Q34707136

Bendamustine: rebirth of an old drug

Q34947495

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

Q36807184

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

Q38059720

Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab.

Q46735737

Revised response criteria for malignant lymphoma

Q47582438

Suboptimal dosing of rituximab in male and female patients with DLBCL.

Q51180540

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.

Q51537941

The calculation of actual or received dose intensity: a comparison of published methods.

Q52437931

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.

Q52969991

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Q53171451

The calculation of received dose intensity

Q68588440

P433

issue

P921

main subject

rituximab

bendamustine

non-Hodgkin lymphoma

page(s)

1589-1597

P577

publication date

2016-11-14

P1433

published in

Leukemia & Lymphoma

Q6534493

P1476

title

Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose

P478

volume